Did everyone see the NVLX news yesterday? Nuvilex
Post# of 1086
Posted On: 02/20/2014 8:39:35 AM
Did everyone see the NVLX news yesterday? Nuvilex is getting closer to clinical phase-III trials on it's newly developed pancreatic cancer treatment.
The company's advanced pancreatic cancer treatment that combines the Cell-in-a-Box technology with ifosfamide has provided better results than both gemcitabine alone and the Abraxane-gemcitabine combination. Those results included an increase of about 4 months in median survival time over gemcitabine alone versus the 1.8 months seen with the Abraxane-gemcitabine combination. The results also included a 100% increase in the one-year survival rate as compared to gemcitabine versus a 59% increase for the Abraxane-gemcitabine combination. The results obtained with Nuvilex's treatment are even more noteworthy given that only one-third of the dose of ifosfamide normally used to treat other types of cancer was used in the Phase II pancreatic cancer trials.
(0)
(0)PharmaCyte Biotech Inc. (PMCB) Stock Research Links
Scroll down for more posts ▼